These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30148617)

  • 1. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
    Manley PW; Caravatti G; Furet P; Roesel J; Tran P; Wagner T; Wartmann M
    Biochemistry; 2018 Sep; 57(38):5576-5590. PubMed ID: 30148617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
    J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
    BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
    Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
    J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
    Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
    Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
    Stone RM; Manley PW; Larson RA; Capdeville R
    Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
    Tollkuci E
    J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin approved for FLT3-mutated AML.
    Levis M
    Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
    Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
    Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
    Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.